CL2018002683A1 - Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata - Google Patents

Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata

Info

Publication number
CL2018002683A1
CL2018002683A1 CL2018002683A CL2018002683A CL2018002683A1 CL 2018002683 A1 CL2018002683 A1 CL 2018002683A1 CL 2018002683 A CL2018002683 A CL 2018002683A CL 2018002683 A CL2018002683 A CL 2018002683A CL 2018002683 A1 CL2018002683 A1 CL 2018002683A1
Authority
CL
Chile
Prior art keywords
prostate
endoradio
high affinity
cancer therapy
membrane
Prior art date
Application number
CL2018002683A
Other languages
English (en)
Inventor
Sangeeta Ray
Martin G Pomper
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of CL2018002683A1 publication Critical patent/CL2018002683A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPUESTOS QUE COMPRENDEN UN RADIOMETAL ADECUADO PARA RADIOTERAPIA Y USO PARA TRATAR UNO O MÁS TUMORES O CÉLULAS QUE EXPRESAN PSMA.
CL2018002683A 2016-03-22 2018-09-21 Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata CL2018002683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22

Publications (1)

Publication Number Publication Date
CL2018002683A1 true CL2018002683A1 (es) 2019-04-22

Family

ID=59899817

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002683A CL2018002683A1 (es) 2016-03-22 2018-09-21 Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata

Country Status (27)

Country Link
US (3) US11458213B2 (es)
EP (3) EP4385981A1 (es)
JP (4) JP7073270B2 (es)
KR (4) KR20250057132A (es)
CN (3) CN109311827B (es)
AU (1) AU2017238181B2 (es)
BR (1) BR112018069507A2 (es)
CA (1) CA3018709A1 (es)
CL (1) CL2018002683A1 (es)
CY (1) CY1124487T1 (es)
DK (2) DK3925952T3 (es)
ES (2) ES2877572T3 (es)
FI (1) FI3925952T3 (es)
HR (2) HRP20211386T1 (es)
HU (2) HUE065327T2 (es)
LT (2) LT3433238T (es)
MX (1) MX384823B (es)
PH (1) PH12018502048A1 (es)
PL (2) PL3925952T3 (es)
PT (2) PT3925952T (es)
RS (2) RS65188B1 (es)
RU (2) RU2021115958A (es)
SA (1) SA518400103B1 (es)
SI (2) SI3925952T1 (es)
TR (1) TR201813644T1 (es)
WO (1) WO2017165473A1 (es)
ZA (1) ZA201806389B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017311510B2 (en) 2016-08-10 2021-11-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
BR112020011727A2 (pt) 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
US20200297877A1 (en) * 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
EP3749663A1 (en) * 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
US11813340B2 (en) * 2018-02-06 2023-11-14 The Johns Hopkins University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
HRP20230604T1 (hr) 2018-03-30 2023-09-29 Futurechem Co., Ltd. Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate
WO2019240884A2 (en) 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
EP3856261A1 (en) * 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
WO2020139012A1 (ko) * 2018-12-27 2020-07-02 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
PH12021553284A1 (en) * 2019-07-02 2022-08-01 Advanced Accelerator Applications Italy Srl Prostate specific membrane antigen (psma) ligands and uses thereof
CN114096526A (zh) * 2019-07-02 2022-02-25 诺华股份有限公司 前列腺特异性膜抗原（psma）配体及其用途
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
JP2023522983A (ja) * 2020-04-24 2023-06-01 ラジオメディックス インコーポレイテッド 前立腺がんの診断および処置のための組成物、キットおよび方法
IL297323A (en) 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
EP4247798B1 (en) * 2020-11-19 2025-08-27 Novartis AG Synthesis of prostate specific membrane antigen (psma) ligands
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
US20240299596A1 (en) * 2021-06-17 2024-09-12 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
AU2023413150A1 (en) * 2022-12-21 2025-06-26 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
CN121604981A (zh) 2023-07-21 2026-03-03 诺华公司 靶向psma的放射性配体治疗方案

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700234T3 (es) * 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
JP2012511024A (ja) 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 癌の治療及び撮像用のｃａ−ｉｘ特異性放射性医薬品
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
ES2729555T3 (es) * 2011-11-30 2019-11-04 Univ Johns Hopkins Inhibidores homomultivalentes y heteromultivalentes de antígeno de membrana específico de próstata (PMSA) y usos de los mismos
EP3939972A1 (en) * 2013-01-14 2022-01-19 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
EP3456700A1 (en) * 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN106660943B (zh) * 2014-05-06 2020-03-17 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
EP3183236B1 (en) 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
EP3212610B1 (en) * 2014-10-30 2020-10-28 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

Also Published As

Publication number Publication date
RS62274B1 (sr) 2021-09-30
BR112018069507A2 (pt) 2019-01-29
PT3925952T (pt) 2023-12-13
JP7073270B2 (ja) 2022-05-23
EP3433238B1 (en) 2021-06-16
US20250195700A1 (en) 2025-06-19
PH12018502048A1 (en) 2019-07-01
JP2022116028A (ja) 2022-08-09
US11458213B2 (en) 2022-10-04
JP2024050608A (ja) 2024-04-10
PL3925952T3 (pl) 2024-04-22
MX2018011519A (es) 2019-01-28
SI3433238T1 (sl) 2021-11-30
CN109311827A (zh) 2019-02-05
SA518400103B1 (ar) 2022-03-20
ZA201806389B (en) 2024-01-31
LT3433238T (lt) 2021-09-27
CN114716387B (zh) 2025-04-01
ES2877572T3 (es) 2021-11-17
DK3925952T3 (da) 2024-02-05
AU2017238181A1 (en) 2018-10-18
EP3433238A1 (en) 2019-01-30
EP4385981A1 (en) 2024-06-19
LT3925952T (lt) 2024-01-25
NZ746701A (en) 2024-12-20
NZ786380A (en) 2025-05-02
KR20220063298A (ko) 2022-05-17
MX384823B (es) 2025-03-14
SI3925952T1 (sl) 2024-03-29
TR201813644T1 (tr) 2018-11-21
US20230015736A1 (en) 2023-01-19
DK3433238T3 (da) 2021-09-06
PL3433238T3 (pl) 2021-12-13
EP3925952A1 (en) 2021-12-22
EP3925952B1 (en) 2023-11-29
HRP20240215T1 (hr) 2024-04-26
HUE055607T2 (hu) 2021-12-28
CN109311827B (zh) 2022-04-12
US20200155713A1 (en) 2020-05-21
RU2749399C2 (ru) 2021-06-09
HRP20211386T1 (hr) 2021-12-10
JP2019519467A (ja) 2019-07-11
CN120172884A (zh) 2025-06-20
RU2018133693A (ru) 2020-04-22
AU2017238181B2 (en) 2021-05-27
RS65188B1 (sr) 2024-03-29
CA3018709A1 (en) 2017-09-28
RU2018133693A3 (es) 2020-04-22
PT3433238T (pt) 2021-07-28
HUE065327T2 (hu) 2024-05-28
FI3925952T3 (fi) 2024-02-13
CY1124487T1 (el) 2022-07-22
EP3433238A4 (en) 2019-09-11
WO2017165473A1 (en) 2017-09-28
JP2026021351A (ja) 2026-02-10
KR20250057132A (ko) 2025-04-28
KR102396307B1 (ko) 2022-05-09
CN114716387A (zh) 2022-07-08
KR20180134918A (ko) 2018-12-19
RU2021115958A (ru) 2021-07-12
KR20230147751A (ko) 2023-10-23
ES2972148T3 (es) 2024-06-11

Similar Documents

Publication Publication Date Title
CL2018002683A1 (es) Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
MX2017013178A (es) Terapia de combinacion para cancer.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2020006668A (es) Anticuerpos para lilrb2.
MX2017005553A (es) Terapia de combinacion para cancer.
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
AR111651A1 (es) Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
UY36968A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
MX2016015614A (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
CO2021010032A2 (es) Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cáncer de pulmón
CR10325A (es) Diagnosticos y tratamientos para tumores
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
GEAP202114132A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
ZA202006008B (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer